U-92,016-A

U-92,016-A is a serotonin receptor antagonist that was first synthesized and studied in the late 20th century. It is known for its selective antagonism of the 5-HT2A receptor, a subtype of the serotonin receptor. This makes U-92,016-A a valuable tool in the research of serotonin and its role in the central nervous system.

History

U-92,016-A was first synthesized by the pharmaceutical company Upjohn in the 1980s. The compound was part of a series of drugs designed to selectively target different subtypes of the serotonin receptor. The goal of this research was to better understand the role of serotonin in the brain and potentially develop new treatments for disorders related to serotonin dysfunction.

Pharmacology

U-92,016-A is a selective antagonist of the 5-HT2A receptor. This means it binds to this receptor and blocks its activation by serotonin. The 5-HT2A receptor is one of the most widely distributed subtypes of the serotonin receptor in the brain, and it is thought to play a key role in many different neurological and psychiatric disorders.

Research Applications

Due to its selective antagonism of the 5-HT2A receptor, U-92,016-A has been used in a variety of research studies. These include investigations into the role of serotonin in mood disorders, anxiety disorders, and schizophrenia. The drug has also been used to study the effects of serotonin on sleep, appetite, and sexual behavior.

See Also

• Serotonin
• 5-HT2A receptor
• Receptor antagonist
• Upjohn